Targeting PI3Kδ: emerging therapy for chronic lymphocytic leukemia and beyond

Medicinal Research Reviews
Manman WeiAo Zhang

Abstract

Chronic lymphocytic leukemia (CLL) remains the most incurable leukemia. Early chemotherapeutic treatments, including alkylating agents, purine nucleoside derivatives, and immunotherapeutic antibodies, only show limited benefits for patients but severe off-target related side effects. Recent advances in understanding of the critical molecular pathways of regulating proliferation and survival of B-CLL cells have spurred a new therapeutical strategy by selectively targeting phosphoinositide 3-kinase delta (PI3Kδ). Idelalisib, a first-in-class PI3Kδ-selective small molecule has received the FDA's fast-track approval in July of 2014 as a new treatment of CLL, indolent B-cell non-Hodgkin's lymphoma, and relapsed small lymphocytic lymphoma. Undoubtedly, the success of idelalisib has provided a solid support in the development of PI3Kδ-specific inhibitors and reformed the concept of treating CLL. However, the number of reported selective inhibitors of PI3Kδ is very limited and very few have advanced into clinical trials. The mechanism of their actions remains elusive. More profound understanding on the modes of action of new PI3Kδ inhibitors will further validate the PI3Kδ-targeting strategy, and help to identify biomarkers capable of ...Continue Reading

References

Jan 1, 1994·Breast Cancer Research and Treatment·P V PlourdeM Dukes
Apr 29, 1997·Proceedings of the National Academy of Sciences of the United States of America·B VanhaesebroeckM D Waterfield
Jul 1, 1997·Trends in Biochemical Sciences·B VanhaesebroeckM D Waterfield
Jun 1, 2002·Science·Lewis C Cantley
Jul 3, 2002·Nature Reviews. Cancer·Igor Vivanco, Charles L Sawyers
Dec 4, 2002·Nature Reviews. Immunology·Hiroaki Niiro, Edward A Clark
Aug 21, 2003·Biochemical and Biophysical Research Communications·Chanchal SadhuDonald E Staunton
Jun 29, 2004·Molecular Immunology·Joseph M Dal PortoJohn Cambier
Feb 25, 2005·The New England Journal of Medicine·Nicholas ChiorazziManlio Ferrarini
Dec 13, 2005·Nature Reviews. Cancer·Andreas G BaderPeter K Vogt
Nov 7, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter HillmenJiri Mayer
Feb 6, 2008·Bioorganic & Medicinal Chemistry Letters·Frédéric StaufferCarlos García-Echeverría
Feb 8, 2008·Inflammopharmacology·S K Kulkarni, V P Singh
Feb 3, 2009·Biological & Pharmaceutical Bulletin·Dexin KongTakao Yamori
Mar 21, 2009·Trends in Biochemical Sciences·Klaartje KokBart Vanhaesebroeck
Jul 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephan StilgenbauerUNKNOWN German Chronic Lymphocytic Leukemia Study Group
Aug 1, 2009·Nature Reviews. Drug Discovery·Pixu LiuJean J Zhao
Aug 5, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wolfgang U KnaufMarco Montillo
Aug 20, 2009·Current Medicinal Chemistry·Dexin Kong, Takao Yamori
Aug 20, 2009·Current Topics in Medicinal Chemistry·Michael K Ameriks, Jennifer D Venable
Dec 4, 2009·Nature Reviews. Cancer·Thorsten ZenzStephan Stilgenbauer
Jan 19, 2010·Nature Chemical Biology·Alex BerndtRoger L Williams
Feb 25, 2010·Cancer Research·Paul WorkmanRob L M van Montfort
May 12, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D Cheson
Jul 10, 2010·OncoTargets and Therapy·Carmen Diana Schweighofer, Clemens-Martin Wendtner
Sep 8, 2010·Seminars in Cancer Biology·Graham Packham, Freda Stevenson

❮ Previous
Next ❯

Citations

Sep 15, 2015·Acta Pharmacologica Sinica·Xiang WangLing-hua Meng
Mar 23, 2017·Bioorganic & Medicinal Chemistry Letters·Minhang XinSan-Qi Zhang
Jan 29, 2017·Bioorganic & Medicinal Chemistry·Michelle S MillerSandra B Gabelli
Nov 2, 2019·Expert Opinion on Therapeutic Patents·Yifan FengMinhang Xin
Jan 8, 2016·The Journal of Immunology : Official Journal of the American Association of Immunologists·Donald T GraciasPeter D Katsikis
Dec 15, 2020·OncoTargets and Therapy·Jiamu WangShuzhao Jia
Apr 3, 2021·Journal of Medicinal Chemistry·Joey L MethotJason D Katz
Apr 16, 2019·Journal of Medicinal Chemistry·Joey L MethotJason D Katz

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Related Papers

Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
Yvonne G HewettBinay K Shah
Cancer Control : Journal of the Moffitt Cancer Center
Marays Veliz, Javier Pinilla-Ibarz
The New England Journal of Medicine
Ajay K GopalGilles A Salles
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Qingshan YangVarsha Gandhi
© 2021 Meta ULC. All rights reserved